Takeda Pharmaceutical Co. TAK
18.86
0.27
1.45%
as of 25 Sep
- Market cap
- $59.2B
- P/E
- 28.4×
Follow TAK
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 4.42% | 0.00% | 0.00% | 4.39% |
+8 more TTM periods Free account |
|
| 2.15% | 0.00% | 0.00% | 2.13% | ||
ROIC |
2.88% | 0.00% | 0.00% | 2.42% | |
Return on Tangible Assets |
13.40% | 0.00% | 0.00% | 13.48% | |
Average Days of Receivables |
73.31 | 0.00 | 0.00 | 57.31 | |
Free Cash Flow per Share |
2.35 | 0.00 | 0.00 | 2.02 | |
Free Cash Flow |
7,420.86 | 10,878.22 | 8,314.41 | 6,324.44 | |
Capital Expenditures |
(3,704.87) | (4,954.63) | (3,167.12) | (3,696.62) | |
Piotroski F-Score |
6.00 | — | — | 6.00 | |
| Other line items | |||||
Cash ROIC |
13.56% | 18.37% | 13.49% | 12.32% | |
Accounts Receivable Turnover |
5.52 | 0.00 | 0.00 | 6.29 | |
Accounts Payable Turnover |
3.50 | 0.00 | 0.00 | 3.07 | |
Inventory Turnover |
1.18 | 0.00 | 0.00 | 1.21 | |
Average Days of Payables |
100.31 | 0.00 | 0.00 | 103.42 | |
Days of Inventory on Hand |
324.95 | 0.00 | 0.00 | 304.55 | |
Tax Rate |
(0.17) | — | — | 0.10 | |
Research and Development Expense of Revenue |
14.77% | — | — | 15.57% | |
Selling, General and Administrative Expense of Revenue |
23.99% | — | — | 24.14% | |
Share Based Compensation of Revenue |
2.33% | 0.00% | 0.00% | 2.43% | |
Interest Coverage |
0.00 | — | — | 0.00 | |
Operating CF/Net income |
5.21 | 0.00 | 0.00 | 4.68 | |
Depreciation/Fixed assets |
0.53 | 0.73 | 0.56 | 0.56 | |
Capex/Depreciation |
(0.52) | (0.50) | (0.42) | (0.49) | |
Revenue per Share |
9.49 | — | — | 9.54 | |
Operating CF per Share |
3.52 | 0.00 | 0.00 | 3.20 | |
Capex per Share |
(1.17) | 0.00 | 0.00 | (1.18) | |
Capex to Sales |
0.12 | 0.00 | 0.00 | 0.12 | |
Net Profit Margin |
7.12% | — | — | 7.17% |
Columns are period end dates